Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCSK9 inhibitor in CABG patients
NCT06730802Not yet recruiting
- Sponsor
- Nanjing Medical University
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Randomised trial in Myocardial ischemia (MI) and coronary heart disease (CHD) (2 arms), sponsored by Nanjing Medical University. Primary endpoint: Major Adverse Cardiovascular and Cerebrovascular Events at 6 months. Planned start Jan 2025; status: not yet recruiting.
02
Conditions
Myocardial ischemia (MI)coronary heart disease (CHD)
Beyond the preview
Go deeper on NCT06730802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06730802.